Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis-Reference-Cited by-同舟云学术

Differentiation of ovarian serous carcinoma from ovarian clear cell carcinoma using a 10-gene signature selected by comprehensive gene expression analysis

Published:2024 Issue:2 Volume:70 Page:65-73
ISSN:0016-2590
Container-title:FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
language:en
Short-container-title:FJMS

Author:

Nomura Shinji¹,Watanabe Takafumi¹,Honma Reiko²,Matsukura Susumu³,Ito Emi⁴,Imai Jun-ichi⁴,Kiko Yuichiro⁵,Suzuki Osamu⁵,Hashimoto Yuko⁵,Kojima Manabu¹,Furukawa Shigenori¹,Soeda Shu¹,Watanabe Shinya⁴,Fujimori Keiya¹

Affiliation:

1. Department of Obstetrics and Gynecology, Fukushima Medical University

2. Nippon Gene Co., Ltd.

3. Medicrome Inc.

4. Translational Research Center, Fukushima Medical University

5. Department of Diagnostic Pathology, Fukushima Medical University

Publisher

The Fukushima Society of Medical Science

Link

https://www.jstage.jst.go.jp/article/fms/70/2/70_23-00011/_pdf

Reference31 articles.

1. 1. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world:epidemiology and risk factors. Int J Womens Health, 11:287-299, 2019.

2. 2. Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer, 60:49-58, 2016.

3. 3. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol, 109:370-376, 2008.

4. 4. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, et al. Rethinking ovarian cancer II:reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer, 15:668-679, 2015.

5. 5. Babaier A, Mal H, Alselwi W, Ghatage P. Low-Grade Serous Carcinoma of the Ovary:The Current Status. Diagnostics (Basel), 12:458, 2022.